Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft

Inclusion Criteria:

* Multiple myeloma de novo.
* Stage DS (Durie-Salmon) : III, II, I with at least 1 symptomatic bone lesion (confirmed by radiology).
* Age \> 65 years
* Indication for a first line treatment with induction, stem cell autologous graft and consolidation
* Available documentation including cytogenetic and International Staging System (ISS) of the initial diagnosis before inclusion,
* Effective contraceptive method for men with a partner of childbearing age during all the treatment period and within 6 months after the last cure
* Affiliated to social security
* Written informed consent
* Willingness and ability to respect the visits and all the demands required by the study
* Patient eligible to a high dose chemotherapy and fulfilling the following biological criteria :

  * Neutrophils ≥ 1,0 × 109/L
  * Platelets ≥ 75 ×109/L (platelets transfusions are not allowed within 3 days before inclusion)
  * Total bilirubin ≤ 1,5 × upper limit.
  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × upper limit
  * Creatinin clearance \> 50 mL/min

Exclusion Criteria:

* Diagnosis and treatment for any other cancer within five years before inclusion or any diagnosis for any cancer. Patients with a skin cancer (except melanoma or carcinoma in situ) are not excluded in case of complete resection.
* Central nervous system disease
* Infection requiring an intravenous (IV) antibiotherapy or any severe infection within 14 days before inclusion
* Diagnosis of any of the following diseases : Waldenström disease, POEMS (polyneuropathy, endocrinopathy, organomegaly, monoclonal gammapathy and skin lesions), plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome or myeloproliferative disorder.
* Uncontrolled cardiopathy including : uncontrolled hypertension, uncontrolled heart arrhythmia, nonsymptomatic congestive cardiac failure, unstable angina or myocardial infarction within 6 months before inclusion
* Active infection with hepatitis B or C virus ; positive HIV serology
* Any comorbidity or severe concomitant disease incompatible with the patient inclusion or interfering with the safety assessment of the study treatments.
* Psychiatric history or any social condition limiting the patient compliance.
* Documented allergy to any studied treatment or any of their components.
* Disability to take oral treatments, inability or refusal to adhere to treatment constraints, or any digestive surgery interfering with oral absorption or treatment tolerance.
* Any experimental treatment within 30 days prior to the administration of the first dose of the studied treatmentParticipation to another clinical trial
* Prior participation to a clinical trial with elotuzumab, no matter the arm of treatment.
* Administration of any pharmaceutical speciality acting against myeloma - such as systemic corticosteroids (\>10 mg of prednisone equivalent a day) or clarithromycin - within the month prior to the inclusion. In case of emergency, patients can receive dexamethasone (40mg/day, 4 consecutive days, maximum dose of 160mg) between screening and randomization